Viveve Medical Inc.

Viveve, Inc. is a women's health company committed to enhancing women's lives by providing clinically proven, high quality products that improve their overall health and well-being.

Viveve's lead product, the globally patented, non-surgical Viveve® System, is a revolutionary medical device that remodels and restores vaginal collagen using reverse-thermal gradient radiofrequency technology in a single 30-minute out-patient session. The Viveve System has regulatory approval in many countries globally and is available through physician import license in Japan.

Expert Comments:

As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice.
read more >
Brian Marckx, Zacks Small-Cap Research (2/21/17)
"For Viveve Medical Inc., Q4/16 marked the sixth straight quarter of sequential double-digit percentage increase in revenue growth. It also set new records in both the number of consoles and treatment tips sold. . .we remain very encouraged that this continues to show a significant ramp." -Zacks Small-Cap Research

Jeff Cohen, Ladenburg Thalmann (2/17/17)
"Viveve Medical Inc. announced financial results from Q4 and full year 2016 and held a conference call to discuss. The company announced revenue of $2.45 million and net loss of $5.8 million and $0.55 per share as compared with consensus of $2.14 million and loss of $5.1 million and $0.48 and our estimates for $2.05 million and loss of $5.3 million and $0.49. . .Q4 revenue increased 226% on an annual basis and 32% equentially as the company’s commercial and clinical activities continue to drive adoption and penetration in the marketplace."

Anthony Vendetti, Maxim Group (2/17/17)
"We would continue to be buyers of Viveve Medical Inc. following its sixth consecutive quarter of double-digit revenue growth driven by increasing system sales, and disposable treatment tip unit sales that increased more than 300% sequentially. . .VIVE is currently awaiting FDA authorization to begin a study for the indication of improving sexual function. Moreover, in January 2017, it announced regulatory clearances in Columbia, Costa Rica, and Malaysia. . .we believe management's focus on attaining additional regulatory clearances, supporting its global distribution partners, expanding its direct sales force, and investing in market awareness, should position it for continued growth."

Brian Marckx, Zacks Equity Research (1/30/17)
"Viveve Medical Inc. recently crossed what we characterize as a major milestone with the entry of the Viveve System into the U.S. market and the recent announcement last week that they have begun deployment of their initial domestic sales force. While other energy-based devices targeted to the U.S. vaginal laxity market have preceded Viveve's entry, none are FDA- cleared for an indication related to that use. . .the Viveve System is the only device that has demonstrated significant efficacy for the improvement in vaginal laxity and/or sexual function."

The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S.
read more >
Brian Marckx, Zacks Equity Research (11/16/16)
"Viveve Medical Inc.'s randomized clinical study results confirmed earlier findings that Viveve System significantly improves sexual function and reduces vaginal laxity. This marketing study, along with data from previous studies and the recent significantly beefed-up distribution is expected to help accelerate the roll-out of the Viveve System. . .Geneveve is now cleared for sale in 49 countries and the company expects to have approval in another two to four by the end of this year."

CapitalCube (11/14/16)
"Viveve Medical Inc. reports financial results for the quarter ended September 30, 2016. . .VIVE's gross margins widened from 28.60% to 37.37% compared to the same period last year, operating (EBITDA) margins now -248.89% from -528.08%."

More Expert Comments

Experts Following This Company

Jeff Cohen, Analyst – Ladenburg Thalmann
Charles Haff – Craig-Hallum Capital
Brian Marckx, CFA – Zacks Small-Cap Research
Anthony Vendetti – Maxim Group

The information provided above is from analysts, newsletters, the company and other contributors.

Viveve Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
First clinically efficacious technology addressing a $7B market opportunity with limited to no competition
Seasoned medical device executive team with a history of significant successes
Highly undervalued stock with >90% ownership from high quality, institutional healthcare investors